Linoleamide DEA

Linoleamide DEA and pregnancy

Not Recommended

• Known teratogen
• Absorbed into the body
• Fetal development

Linoleamide DEA is a diethanolamine (DEA)-based ingredient used to control viscosity in cosmetic products. DEA compounds can be absorbed through the skin and have been shown to accumulate in body tissues, including potentially crossing the placental barrier. Animal studies have shown that DEA exposure during pregnancy can affect fetal brain development. According to research published in toxicology journals, maternal exposure to DEA was associated with neural tube defects and decreased fetal weight in laboratory animals. The compound can interfere with choline metabolism, which is critical for fetal brain and nervous system development. While human studies are limited, the mechanism of harm and animal evidence raise serious concerns about prenatal exposure. The European Union has restricted DEA-based ingredients in cosmetics due to health concerns, and many medical professionals advise pregnant women to avoid these compounds. ACOG recommends avoiding known or suspected teratogens and harmful chemicals during pregnancy. Given the evidence of developmental toxicity in animals and the ingredient's ability to be absorbed systemically, it's advisable to avoid products containing linoleamide DEA during pregnancy.

Linoleamide DEA and breastfeeding

Not Recommended

• Passes into breast milk
• Infant exposure

Linoleamide DEA is a diethanolamine (DEA) compound that can be absorbed through the skin into systemic circulation. DEA has been shown to accumulate in tissues and can potentially transfer to breast milk. Studies have demonstrated that DEA compounds can be detected in various body tissues after topical application. While specific breast milk transfer data for this compound is limited, the lipophilic nature of the molecule and evidence of systemic accumulation suggest potential for transfer to breastfed infants. The concern is heightened by DEA's classification as a possible carcinogen and its effects on choline metabolism, which could impact infant neurological development. Given the carcinogenic potential and evidence of systemic absorption, many dermatologists and lactation consultants recommend avoiding DEA-based ingredients during breastfeeding. The European Union's restrictions on these compounds reflect broader safety concerns that extend to breastfeeding mothers.

Linoleamide DEA and postpartum

Not Recommended

Linoleamide DEA is a DEA-based thickening agent with known health concerns including carcinogenic potential and skin irritation. While breastfeeding concerns don't apply to non-breastfeeding mothers, the general health risks remain. The carcinogenic potential and potential for endocrine disruption make this ingredient inadvisable even for postpartum women who are not breastfeeding. Many health-conscious consumers and dermatologists recommend avoiding DEA compounds regardless of pregnancy or breastfeeding status due to their long-term health implications.

Linoleamide DEA and trying to conceive

Not Recommended

• Fertility effects
• Hormone disruptor
• Builds up in tissue

Linoleamide DEA is a DEA-based compound with potential endocrine-disrupting properties and evidence of tissue accumulation. Given its classification as a possible carcinogen and developmental toxicant, avoiding exposure before and during conception is advisable. The same concerns that apply during pregnancy—interference with choline metabolism and potential developmental effects—make this ingredient particularly important to avoid while trying to conceive. DEA compounds can accumulate in tissues over time, so discontinuing use before conception allows for clearance from the body. Many fertility specialists recommend avoiding known endocrine disruptors and potential teratogens during the pre-conception period.

Linoleamide DEA and PCOS

Not Recommended

• Endocrine disruptor
• Can inflame skin

Linoleamide DEA is a diethanolamine-based ingredient that has been shown to have potential endocrine-disrupting properties. DEA compounds can interfere with normal hormonal signaling and have been linked to thyroid hormone disruption in animal studies. For women with PCOS, who already have hormonal imbalances, exposure to endocrine-disrupting chemicals is particularly concerning. While specific studies on DEA and PCOS are lacking, the compound's potential to interfere with hormone metabolism could theoretically worsen hormonal dysregulation. Additionally, the inflammatory potential of this irritating ingredient may not be ideal for PCOS-related skin inflammation. Given the hormonal sensitivities associated with PCOS and the known endocrine-disrupting potential of DEA compounds, it's advisable for women with PCOS to avoid products containing linoleamide DEA. Safer thickening and viscosity-controlling alternatives are widely available.

Linoleamide DEA and general use

Not Recommended

• Carcinogen concern
• Endocrine disruptor
• Irritant

Linoleamide DEA is a viscosity-controlling agent and thickener derived from linoleic acid and diethanolamine (DEA). It helps create stable, thick formulations in cosmetic products. However, DEA-based ingredients have significant health concerns associated with them. The International Agency for Research on Cancer (IARC) classifies diethanolamine as a possible human carcinogen (Group 2B). DEA compounds can form carcinogenic nitrosamines when combined with certain preservatives or other ingredients. Studies have shown that DEA can be absorbed through the skin and accumulate in organs including the liver, kidney, and brain. The FDA has expressed concerns about chronic exposure to DEA-based ingredients. Additionally, these compounds may cause skin and eye irritation in many users. The European Union has restricted the use of DEA and its derivatives in cosmetics due to cancer concerns and potential for nitrosamine formation. In the United States, while not banned, California's Proposition 65 lists DEA as a substance that may cause cancer. Many health-conscious brands have reformulated to eliminate DEA-based ingredients in favor of safer alternatives. Consumers concerned about long-term health risks may wish to avoid products containing linoleamide DEA and other DEA compounds.

Everything else flagged for the same profiles

• Flagged in pregnancy
• Flagged in breastfeeding
• Flagged in trying to conceive
• Flagged in postpartum
• Flagged in PCOS

Related ingredients

Ingredients suggested in place of Linoleamide DEA, each one with its own page here.

• Glycerin

Ingredients that raise the same concerns.

• FormaldehydeCan inflame skin, Carcinogen concern, Known teratogen
• PhenolCan inflame skin, Carcinogen concern, Known teratogen
• Basic Green 4Carcinogen concern, Known teratogen, Endocrine disruptor
• Tussilago Farfara ExtractCan inflame skin, Carcinogen concern, Known teratogen
• TolueneCarcinogen concern, Known teratogen, Endocrine disruptor
• AcrylamideCarcinogen concern, Known teratogen, Endocrine disruptor

Where this came from

Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.

Assessment last pulled from the ingredient database on 15 September 2026.